Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rocket Pharmaceuticals (RCKT)
NASDAQ:RCKT
Holding RCKT?
Track your performance easily
RCKT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$16.55 - $32.53
Previous Close$18.46
Volume998.25K
Average Volume (3M)812.06K
Market Cap
$1.68B
Enterprise Value$1.43B
Total Cash (Recent Filing)$278.82M
Total Debt (Recent Filing)$25.80M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Nov 06, 2024EPS Estimate
-$0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.79
Shares Outstanding90,975,859
10 Day Avg. Volume1,371,920
30 Day Avg. Volume812,057
Standard Deviation0.18
R-Squared0.10
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)4.36
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-620.17
Enterprise Value/Ebitda-7.46
Forecast
1Y Price Target
$48.63Price Target Upside163.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Rocket Pharmaceuticals News
PremiumStock Analysis & Ideas
Morgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ Stocks
Bulls Say, Bears Say
Bulls Say
Enrollment CompletionRocket Pharma announced the completion of enrollment for its Phase II pivotal study with RP-A501 in Danon disease, which highlights strong demand for the treatment.
Positive Study DataData from the Phase I study of RP-A501 de-risks the pivotal trial, as significant improvements in both co-primary endpoints were seen across all six treated patients.
Potential Accelerated ApprovalExamining RP-A501’s registrational study design shows meaningful potential for an accelerated approval, given the consistent outcomes observed across patients.
Bears Say
Approval DelayDelay in approval of no longer than 6 months is expected.
Financial ImpactChanges reduce PT from $49 to $46.
Regulatory SetbackThe FDA issued a complete response letter (CRL) to Rocket's BLA for Kresladi, requesting more information related to CMC.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
RCKT FAQ
What was Rocket Pharmaceuticals’s price range in the past 12 months?
Rocket Pharmaceuticals lowest stock price was $16.55 and its highest was $32.52 in the past 12 months.
What is Rocket Pharmaceuticals’s market cap?
Currently, no data Available
When is Rocket Pharmaceuticals’s upcoming earnings report date?
Rocket Pharmaceuticals’s upcoming earnings report date is Nov 06, 2024 which is in 31 days.
How were Rocket Pharmaceuticals’s earnings last quarter?
Rocket Pharmaceuticals released its earnings results on Aug 05, 2024. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.722 by -$0.018.
Is Rocket Pharmaceuticals overvalued?
According to Wall Street analysts Rocket Pharmaceuticals’s price is currently Undervalued.
Does Rocket Pharmaceuticals pay dividends?
Rocket Pharmaceuticals does not currently pay dividends.
What is Rocket Pharmaceuticals’s EPS estimate?
Rocket Pharmaceuticals’s EPS estimate is -$0.75.
How many shares outstanding does Rocket Pharmaceuticals have?
Rocket Pharmaceuticals has 90,975,860 shares outstanding.
What happened to Rocket Pharmaceuticals’s price movement after its last earnings report?
Rocket Pharmaceuticals reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.722. Following the earnings report the stock price went up 0.852%.
Which hedge fund is a major shareholder of Rocket Pharmaceuticals?
Among the largest hedge funds holding Rocket Pharmaceuticals’s share is Maverick Capital ltd. It holds Rocket Pharmaceuticals’s shares valued at 85M.
---
Rocket Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.63 (163.43% Upside)
$48.63 (163.43% Upside)
Blogger Sentiment
Bullish
RCKT Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 18.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $371.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.29%
12-Months-Change
Fundamentals
Return on Equity
-64.31%
Trailing 12-Months
Asset Growth
-3.33%
Trailing 12-Months
Company Description
Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.
---
RCKT Stock 12 Month Forecast
Average Price Target
$48.63
▲(163.43% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
BioMarin Pharmaceutical
―
Bluebird Bio
―
Fate Therapeutics
―
Best Analysts Covering RCKT
1 Year
1 Year Success Rate
14/22 ratings generated profit
1 Year Average Return
+28.10%
reiterated a buy rating 11 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +28.10% per trade.
---